Primary tumor reoccurrence often occurs following surgical resection in glioblastoma multiforme patients. Current hydrogel approaches deliver therapeutics using light or pH, but these approaches are limited by the tumor microenvironment. Researchers have developed an injectable hydrogel with unique materials that can be activated by X-ray irradiation for sustained, on-demand therapeutic delivery. These hydrogels can be loaded with CT contrast agents and therapeutic drugs without affecting their functionality, morphology, or injectability.
Published: 8/6/2026